The steady gross margin expansion from 66.3% to 72.8% over ten quarters reflects scale benefits and cost efficiencies in the Zio service model. Operating margin improvement to -1.1% in 2026Q2, from -28.9% in 2024Q1, suggests that fixed costs are being absorbed by higher volumes, though the company remains unprofitable on a GAAP basis. The 2025Q4 positive operating income of $8.8M appears to be a turning point, but sustainability depends on maintaining reimbursement rates and controlling clinical labor costs.

Despite the improvement, ROIC remains negative at -0.3% in 2026Q2, reflecting that the company is still investing heavily in growth and has not yet achieved profitability. The trend from -13.2% to -0.3% suggests that the business is approaching a breakeven point, but the negative returns indicate that capital deployed has not yet yielded positive returns. Investors should monitor whether the company can sustain this trajectory and eventually generate positive ROIC, which would validate the capital allocation strategy.

The CCC improvement from 67 to 49 days over ten quarters indicates better working capital management, with DSO declining from 52 to 34 days and DIO increasing slightly from 30 to 35 days. The reduction in DSO suggests improved billing and collection processes, while the stable DIO reflects efficient inventory management. However, DPO remains low at 19 days, indicating limited supplier leverage, which may be a structural characteristic of the device manufacturing model.

The D/E ratio has improved significantly, but the absolute debt level remains substantial, and interest coverage of 0.88 in 2026Q2 indicates that operating income is barely sufficient to cover interest expenses. The improvement in D/E is partly due to equity growth from external capital, not retained earnings, as the accumulated deficit deepened. The stability of debt levels over ten quarters suggests potential refinancing needs, which could be costly in a high-rate environment, warranting close monitoring.

The current ratio remains above 3, suggesting adequate short-term liquidity, but the trend is concerning as cash reserves have more than halved over ten quarters. The decline in cash is partly due to operating losses and investments in growth, though the positive FCF in 2026Q2 may help stabilize the position. Under severe stress, the company could face liquidity constraints if revenue growth stalls or reimbursement cuts materialize, but the current ratio suggests near-term solvency is not at risk.